{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T15:40:49Z","timestamp":1762875649737},"reference-count":15,"publisher":"Spandidos Publications","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.3892\/ol.2014.2801","type":"journal-article","created":{"date-parts":[[2014,12,12]],"date-time":"2014-12-12T13:23:26Z","timestamp":1418390606000},"page":"735-738","source":"Crossref","is-referenced-by-count":11,"title":["Detection of JAK2 V617F mutation increases the diagnosis of myeloproliferative neoplasms"],"prefix":"10.3892","volume":"9","author":[{"given":"SHU-PENG","family":"ZHANG","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"HUI","family":"LI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"REN-SHENG","family":"LAI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2014,12,12]]},"reference":[{"key":"key20180108103338_b1-ol-09-02-0735","first-page":"305","article-title":"JAK2 gene mutation and MPN","volume":"27","author":"Tao","year":"2006","journal-title":"China Medical Abstracts (Internal Medicine)"},{"key":"key20180108103338_b2-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organiszation (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"key20180108103338_b3-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180108103338_b4-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"key20180108103338_b5-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"key20180108103338_b6-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"key20180108103338_b7-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180108103338_b8-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"key":"key20180108103338_b9-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"key20180108103338_b10-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1182\/asheducation-2005.1.195","article-title":"A unique activating mutation in JAK2 (V617F) is at the origin of polycythemia vera and allows a new classification of myeloproliferative diseases","volume":"1","author":"Vainchenker","year":"2005","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"key20180108103338_b11-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1309\/AJCPK7KGOWPHYWM0","article-title":"High percentage of JAK2 exon 12 mutation in Asian patients with polycythemia vera","volume":"134","author":"Yeh","year":"2010","journal-title":"Am J Clin Pathol"},{"key":"key20180108103338_b12-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3324\/haematol.11581","article-title":"JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis","volume":"93","author":"Schmitt-Graeff","year":"2008","journal-title":"Haematologica"},{"key":"key20180108103338_b13-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.canlet.2009.02.010","article-title":"Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications","volume":"284","author":"Panani","year":"2009","journal-title":"Cancer Letters"},{"key":"key20180108103338_b14-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s12308-008-0014-8","article-title":"The implication of identifying JAK2 (V617F) in myeloproliferative neoplasms and myelodysplastic syndromes with bone marrow fibrosis","volume":"1","author":"Olsen","year":"2008","journal-title":"J Hematop"},{"key":"key20180108103338_b15-ol-09-02-0735","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/sj.leu.2404948","article-title":"JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials","volume":"22","author":"Pardanania","year":"2008","journal-title":"Leukemia"}],"container-title":["Oncology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/ol.2014.2801\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T11:31:37Z","timestamp":1566127897000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/ol.2014.2801"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,12]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2014,12,12]]},"published-print":{"date-parts":[[2015,2]]}},"alternative-id":["10.3892\/ol.2014.2801"],"URL":"https:\/\/doi.org\/10.3892\/ol.2014.2801","relation":{},"ISSN":["1792-1074","1792-1082"],"issn-type":[{"value":"1792-1074","type":"print"},{"value":"1792-1082","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,12]]}}}